Back to Search
Start Over
Management of cardiovascular risk in patients with multiple myeloma
- Source :
- Blood Cancer Journal, Blood Cancer Journal, Vol 9, Iss 3, Pp 1-12 (2019)
- Publication Year :
- 2019
- Publisher :
- Nature Publishing Group UK, 2019.
-
Abstract
- Multiple myeloma (MM) is a plasma cell malignancy that accounts for 10% of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities or risk factors. MM can cause cardiac comorbidities such as cardiomyopathy and heart failure caused by cardiac amyloidosis and/or anemia. Some of the treatments used in MM can also affect cardiovascular health. Advances in pharmacotherapy for MM, such as the introduction of immunomodulators, proteasome inhibitors, histone deacetylase inhibitors, and monoclonal antibodies, have dramatically improved progression-free survival and life expectancy, but new agent classes are associated with adverse events that were not previously observed on a regular basis, including cardiovascular events. However, with careful risk assessment, monitoring, and prophylactic therapy, many of these cardiovascular complications can be managed or treated successfully. Most routine cardiovascular surveillance is undertaken by the treating hemato-oncologist, but a multidisciplinary approach involving cardiologists may help to optimize patient outcomes. In this review, we survey the cardiac complications commonly reported in patients with MM, discuss how they can be prevented and managed, and summarize the role cardiologists can play in delivering the best possible outcomes for patients with MM and cardiovascular comorbidities.
- Subjects :
- medicine.medical_specialty
Anemia
Cardiomyopathy
Review Article
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Pharmacotherapy
Cardiologists
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Molecular Targeted Therapy
Adverse effect
Physician's Role
Multiple myeloma
business.industry
Disease Management
Hematology
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Combined Modality Therapy
Oncology
Cardiac amyloidosis
Cardiovascular Diseases
030220 oncology & carcinogenesis
Heart failure
business
Risk assessment
Multiple Myeloma
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 20445385
- Volume :
- 9
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Blood Cancer Journal
- Accession number :
- edsair.doi.dedup.....d392fd48bee257c220d1c55472518e32